Clinical trial registry record

Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD

A registered study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Withdrawn.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated July 26, 2017.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02457026
Last registry update
July 26, 2017
Status
Withdrawn
Phase
Phase not reported
Sponsor
Duke University
Enrollment
0
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
0
Population
ALL · 55 Years
Duration
2016-01-01 to 2018-01-01
Intervention
Aflibercept; Triamcinolone Acetonide; Verteporfin
Comparator
Aflibercept Alone
Outcomes measured
Percentage of individuals with resolution or major reduction in PDA — up to 8 weeks after loading dose; Percentage of individuals with sustained visual acuity — 1 year after loading dose; Average number of aflibercept injections — 1 year after loading dose; Frequency of case with progressive disease on therapy — 6 months post-PDT treatment; Mean change in choroidal neovascularization lesion size by fluorescein angiography from baseline — 6 months post-PDT tr…; Mean change in central foveal thickness by SD-OCT — 6 months post-PDT treatment; Mean change in best-corrected ETDRS visual acuity from baseline — 6 months post-PDT treatment; Percentage of participants with 2-line ETDRS visual acuity gain — 6 months post-PDT treatment; Percentage of participants with 2-line ETDRS visual acuity loss — 6 months post-PDT treatment
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON